Compare · GUTS vs MDT
GUTS vs MDT
Side-by-side comparison of Fractyl Health Inc. (GUTS) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GUTS focuses on Medical/Dental Instruments, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $129.97B, about 11124.7x GUTS ($11.7M).
- MDT has been more active in the news (16 items in the past 4 weeks vs 8 for GUTS).
- MDT has more recent analyst coverage (25 ratings vs 6 for GUTS).
- Company
- Fractyl Health Inc.
- Medtronic plc.
- Price
- -
- -
- Market cap
- $11.7M
- $129.97B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 8
- 16
- Recent ratings
- 6
- 25
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest GUTS
- SEC Form 3 filed by new insider Wartell Michael J.
- Fractyl Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
- Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
- Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
- SEC Form 8-K filed by Fractyl Health Inc.
- Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Fractyl Health, Inc. to Contact Law Firm
- GUTS UPCOMING DEADLINE: Levi & Korsinsky Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm
- SEC Form 8-K filed by Fractyl Health Inc.
Latest MDT
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
- Medtronic to announce financial results for its second quarter of fiscal year 2027
- /C O R R E C T I O N - The Michael J. Fox Foundation for Parkinson's Research/
- Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
- Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation